Episode
Novo Nordisk and OpenAI: End to End Pharma AI, the GLP One Race, and the Regulatory Crucible Ahead - May 3, 2026
- Published
- May 3, 2026
- Duration seconds
- 823
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/dx-today-no-hype-podcast-news-about-ai-dx-6434212/episodes/novo-nordisk-and-openai-end-to-end-pharma-ai-the-glp-one-race-and-the-regulatory-crucible-ahead-may-3-2026/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/dx-today-no-hype-podcast-news-about-ai-dx-6434212/novo-nordisk-and-openai-end-to-end-pharma-ai-the-glp-one-race-and-the-regulatory-crucible-ahead-may-3-2026.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Send us Fan Mail Novo Nordisk and OpenAI: End to End Pharma AI, the GLP One Race, and the Regulatory Crucible Ahead - May 3, 2026 The Danish drugmaker behind Ozempic and Wegovy is integrating OpenAI's models across drug discovery, clinical trials, manufacturing, supply chain, and commercial operations, with pilots in twenty twenty six and full integration by year end. Rick Spair and Laura unpack what is real, what is theater, and what the deal signals for the rest of regulated industry. Hos...